November 2025 in “Journal of Investigative Dermatology” Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib effectively regrows scalp hair in most people with severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.
September 2025 in “Journal of the American Academy of Dermatology” Ritlecitinib may help treat alopecia areata by protecting hair follicles.
July 2025 in “Frontiers in Medicine” Baricitinib successfully regrew hair in an 8-year-old boy with alopecia totalis linked to a KRT74 gene variant.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
June 2025 in “bioRxiv (Cold Spring Harbor Laboratory)” In alopecia areata, certain immune cells increase and express a protein linked to immune activation.
Ritlecitinib is a new treatment for severe hair loss in people 12 and older.
May 2025 in “Frontiers in Pharmacology” Targeting gut microbiome and metabolome may help treat autoimmune skin diseases like alopecia areata.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Targeting specific metabolic and ionic pathways may improve alopecia areata treatment.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Targeting specific metabolic and ionic pathways may improve alopecia areata treatment.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
April 2025 in “BMC Immunology” Targeting SIRT1 with antisense oligonucleotides could be a promising treatment for hair loss.
March 2025 in “Drug Development Research” The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.
March 2025 in “Clinical and Experimental Dermatology” Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
January 2025 in “International Journal of Dermatology” Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
December 2024 in “Cureus” Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.
November 2024 in “EMBO Molecular Medicine” JAK inhibitors may reverse early hair loss, but prolonged inflammation can cause permanent hair loss.
Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
August 2024 in “JAAD Case Reports” Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.
August 2024 in “British Journal of Dermatology” Rezpegaldesleukin shows promise for treating severe alopecia areata.
July 2024 in “Journal of Investigative Dermatology” Tailored treatments for alopecia areata show promising results, with pulse steroids effective for mild cases and Ritlecitinib, Dupilumab, or methotrexate and prednisone effective for severe cases.
Baricitinib may not always prevent relapse in alopecia areata.